In AF patients who received warfarin, there was no significant difference between the two groups regarding the therapeutic range (TTR) of anticoagulation (assessed by prothrombin time, prothrombin concentration, and INR) at baseline, 6 months, and 1 year. The gene discussed is F2; the disease is atrial fibrillation.